Navigation Links
Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
Date:3/13/2008

December 2007, Jazz Pharmaceuticals dosed the first patient in an ongoing Phase II clinical trial of JZP-8. Assuming successful results from the Phase II trial, Jazz Pharmaceuticals expects to initiate a Phase III clinical development program for JZP-8 in the first half of 2009.

Jazz Pharmaceuticals' product candidate for once-daily treatment of epilepsy and bipolar disorder, JZP-4, incorporates a new chemical entity that inhibits both sodium and calcium channels in vitro and has shown efficacy in animal models. Two proof-of-concept clinical studies in healthy volunteers and patients demonstrated activity in well-validated epilepsy models. Jazz Pharmaceuticals plans to begin enrolling subjects in a Phase II trial of JZP-4 for the treatment of epilepsy during the third quarter of 2008.

Jazz Pharmaceuticals also disclosed three additional early-stage programs: a solid oral dosage form of sodium oxybate; a new chemical entity that is a structural analog of valproic acid for the treatment of epilepsy and bipolar disorder; and a new chemical entity that is a triple reuptake inhibitor for major depressive disorder. Both of the new chemical entities are in early feasibility studies and Jazz Pharmaceuticals has established clear targets to advance them into full development.

Financial Updates

Jazz Pharmaceuticals provided guidance forecasting selling, general and administrative expenses during 2008 to be in the range of $130 million to $140 million, reflecting the expanded sales force, launch activities related to LUVOX CR and costs associated with being a public company. Research and development spending during 2008 is expected to be in the range of $60 million to $70 million.

Jazz Pharmaceuticals also announced that it has amended its agreement with Solvay Pharmaceuticals, Inc., to defer the payment of milestones triggered by the approval and launch of LUVOX CR.

A webcast of Jazz Pharmaceuticals' Investor Day is available on the i
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
2. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
3. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
4. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
5. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
6. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
7. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
8. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
9. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
10. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
11. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ProFlare ... simple as dragging and dropping footage into the FCPX timeline ... , Including over 80 stunning flares, ProFlare 5K Prism ... the ultimate bundle for adding prismatic refractions to any video. ... movie files designed for Final Cut Pro X, but are ...
(Date:5/22/2015)... Pioneer Millworks, the largest reclaimed wood ... designing with reclaimed wood, introducing their latest reclaimed wood ... Their newest offerings, Vat 35, Reclaimed Teak , ... to America's largest design event. , “Designers, architects, builders, ... anxious to see and feel the variety of wood ...
(Date:5/22/2015)... Liverpool, OH (PRWEB) May 22, 2015 ... announced that Kyle Johnson, the health system’s Chief Financial ... other interests. Johnson has served as the company CFO ... Wesley West will be joining the health system as ... on an interim basis, while the Board of Trustees ...
(Date:5/22/2015)... May 22, 2015 Omar Ahmad Barrada, ... to participate in the 2015 Congress of Future Medical ... as a gathering of “America’s highest achieving high school ... of healthcare, set new goals and learn better study ... live surgery, during which we can ask the surgeons ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... for its treatment by the FDA, following a clinical ... Taxotere survived an average of 11.4 months without disease ... ,The drug will be used before radiation, ... advanced squamous cell head and neck cancer. Its side ...
... human gene therapy for Parkinson's disease has given the green ... reducing symptoms for patients,// according to the reports of two ... yesterday and last week the researchers reported that each of ... trials received some benefit and none had significant side effects. ...
... A new experimental vaccine developed by scientists in the US ... help prevent the disease that has kills one million// people ... S and developed by Walter Reed Army Institute of Research ... percent for up to 18 months after vaccination among children ...
... a computer-driven system can significantly reduce the duration ... the intensive// care unit (ICU), as compared with ... ,The study, which was conducted in five medical-surgical ... appears in the second issue for October 2006 ...
... in the October issue of the Journal of the American ... elderly women who have not received// up to the mark ... compared to the younger lot. , ,David Litvak ... colleagues studied the records of 354 breast cancer patients who ...
... turning out to be a big challenge for law enforcement officials ... from the last decade, lock-ups /arrests due to possession of ice ... ,Yet, despite this entire hullabaloo, scientists have not been able ... that is still unclear about the link between this drug and ...
Cached Medicine News:Health News:Gene therapy Beneficial in Parkinson's Disease 2Health News:Gene therapy Beneficial in Parkinson's Disease 3Health News:Computer-Driven System Reduces Patient Mechanical Ventilation Time Significantly 2
(Date:5/22/2015)... , May 22, 2015  BioLife Solutions, Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues ("BioLife" or the "Company"), announced that the ... Conference. The Company is scheduled to present ... 27, 2015 at the Grand Hyatt Hotel in ...
(Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, ... announced a peer-reviewed publication of the results of ... RGN-259 (RegeneRx,s preservative-free eye drops) for the treatment ... adverse environment (CAE ® ) model.  The exploratory ... results, which were previously disseminated by the Company ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... Henry Schein, Inc. (Nasdaq: HSIC ), the ... practitioners, announced today that it will release its third quarter ... October 29, 2010, and will provide a live webcast of ... 10:00 a.m. Eastern Daylight Time. Speakers on the call will ...
... French genome engineering specialist, today published its consolidated financial ... increased 25% over H1 2009, expenditure increased 50% and ... in cash reserves. During the first half ... new agreements (with BASF Plant Science, Boehringer Ingelheim), published ...
Cached Medicine Technology:Henry Schein to Webcast Third Quarter 2010 Conference Call Friday, October 29, at 10:00 a.m. EDT 2Cellectis Publishes Its Financial Statement for the First Half of 2010 2Cellectis Publishes Its Financial Statement for the First Half of 2010 3
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... complete line of flowmeters, available in ... . They are all available in ... suit your application. With color coded ... gas in use, the Amvex Flowmeter ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... Amvex offers a complete line of ... and CO 2 . They are ... calibrations to best suit your application. ... specific to the gas in use, ...
Medicine Products: